EGFR inhibitors in the treatment of colorectal cancer
https://doi.org/10.17709/2409-2231-2018-5-3-7
Abstract
This ar cle discusses the use of EGFR inhibitors in the treatment of pa ents with colorectal cancer. The mechanisms of their ac on, specifi c manifesta ons of toxicity are considered. A review of current literature data on the use of both approved for clinical use (cetuximab, panitumumab) and an -EGFR an bodies at the stage of clinical trials is presented. EGFR inhibitors are one of the main groups of targeted drugs used to treat pa ents with colorectal cancer. The correla on between toxicity and effi cacy of these drugs is discussed separately. The scope of their applica on is limited to the treatment of disseminated forms of the disease, but in the future the number of available an -EGFR an bodies may grow, the possibility of their use in new condi ons, including in the framework of chemoradiotherapy.
About the Authors
M. В. Zabelin
Institute of postgraduate professional education, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency (SRC-FMBC)
Russian Federation
Competing Interests:
Russian Federation
Maxim В. Zabelin - MD, PhD, DSc, head of the department of oncology and radiology, Institute of postgraduate professional education.
23 Marshala Novikova str., Moscow, 123098
Competing Interests:
No confl ict of interest
A. D. Kaprin
National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Andrey D. Kaprin - academician of RAS, MD, PhD, DSc, professor, Corr. member of the Russian Academy of Education; Honored Physician of the Russian Federation; General Director of NMRRC, Head of Department of Urology with Course of Urological Oncology, Faculty for Postgraduate Training PFUR.
4 Koroleva str., Obninsk, Kaluga region, 249036
Competing Interests:
No confl ict of interest
A. A. Kostin
National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Andrey A. Kostin - MD, PhD, DSc, professor, head of department of urology, oncology and radiology of FAS, Medical institute, RUDN University of Russia; fi rst deputy general director NMRRC MH RF.
4 Koroleva str., Obninsk, Kaluga region, 249036
Competing Interests:
No confl ict of interest
E. V. Gameeva
National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Elena V. Gameeva - MD, PhD, deputy director for medical work.
4 Koroleva str., Obninsk, Kaluga region, 249036
Competing Interests:
No confl ict of interest
S. E. Varlamova
Institute of postgraduate professional education, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency (SRC-FMBC)
Russian Federation
Competing Interests:
Russian Federation
Svetlana E. Varlamova - assistant of the department of oncology and radiology, Institute of postgraduate professional education.
23 Marshala Novikova str., Moscow, 123098
Competing Interests:
No confl ict of interest
References
1. Kiyota A, Shintani S, Mihara M, Nakahara Y, Ueyama Y, Matsumura T, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology. 2002;63(1):92-8. DOI: 10.1159/000065726
2. Iannello A., Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2005 Dec;24(4):48799. DOI: 10.1007/s10555-005-6192-2
3. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2007 Feb 15;120(4):781-7. DOI: 10.1002/ijc.22370
4. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007 Mar 1;13(5):1552-61. DOI: 10.1158/1078-0432.CCR-06-1726
5. Tryakin A.A. Targetnaya terapiya kolorektal’nogo raka, raka zheludka i podzheludochnoi zhelezy. Practical Oncology. 2010;11(3):143-150. (In Russian).
6. Fedyanin MYu, Tryakin AA, Tjulandin SA. Potential predictors of anti-EGFR-treatment efficacy in metastatic colorectal cancer. Oncological Coloproctology. 2013;2:21-30. (In Russian).
7. Artamonova EV. Cetuximab in metastatic colon cancer treatment: skin toxicity and solutions to this problem. Oncological Coloproctology. 2011;3:21-28. (In Russian).
8. Vorontsova KA, Chernoglazova EV, Vyshinskaya GV. Targeted drugs in the second line anticancer therapy of disseminated colorectal cancer. Meditsinskiy Sovet (Medical Council). 2015;8. (In Russian).
9. Besova NS. Evolyutsiya lekarstvennoi terapii disseminirovannogo kolorektal’nogo raka. Targetnaya terapiya. Effective Pharmacotherapy. 2011;25:12-21. (In Russian).
10. Fedyanin MYu, Tryakin AA, Tyulyandin SA. Targetnye preparaty v terapii raka tolstoi kishki. Effective Pharmacotherapy. 2012;36:30-37. (In Russian).
11. Kit OI, Kirichenko EY, Novikova IA, Maksimov AY, Filippova SY, Grankina AO, Zlatnik EY. Colorectal Cancer Immunotherapy: Current State and Prospects (Review). Modern Technologies in Medicine. 2017;9(3):138-150. DOI: 10.17691/stm2017.9.3.18 (In Russian).
12. Dobrova NS. Tsetuksimab v lechenii metastaticheskogo kolorektal’nogo raka. Effective Pharmacotherapy. 2012;35:24-9. (In Russian).
13. Vladimirova LYu, Abramova NA, Storozhakova AE. Targetnaya terapiya anti–EGFR monoklonal’nymi antitelami v lechenii kolorektal’nogo raka. Malignant Tumoursis. 2016;S1:87-91. DOI: 10.18027/2224-5057-2016-4s1-87-91 (In Russian).
14. Gorchakov SV, Pravosudov IV, Vasiljev SV, Oleynik VV, Onoshko MV, Popov DE, et al. Modern approach to treatment of colorectal cancer patients with liver metastases (literature review). Vestnik SPbSU. Medicine. 2015;3:55-68. (In Russian).
15. Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX)±cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Journal of Clinical Oncology. 2006;24(18):3509.
16. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Journal of Clinical Oncology. 2007;25(18):4000.
17. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011 May 20;29(15):2011-9. DOI: 10.1200/JCO.2010.33.5091.
18. Feoktistova P.S., Zaginaiko A.V., Karaseva V.V., Khailenko V.A. Targetnaya terapiya metastaticheskogo kolorektal’nogo raka. Zdravookhranenie Yugry: opyt i innovatsii. 2016;S1:76-84. (In Russian).
19. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10;26(14):2311-9. DOI: 10.1200/JCO.2007.13.1193
20. Goldberg R, Sargent D, Thibodeau S, Mahoney M, Shields A, Chan E, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. Journal of Clinical Oncology. 2010;28(1):3508.
21. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 1;28(31):4697-705. DOI: 10.1200/
22. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med. 2013 Sep 12;369(11):102334. DOI: 10.1056/NEJMoa1305275.
23. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 May 1;25(13):1658-64. DOI: 10.1200/JCO.2006.08.1620
24. Argiles G, Dienstmann R, Elez E, Tabernero J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol. 2012 Apr;8(4):373-89. DOI: 10.2217/fon.12.20
25. Jin T, Zhu Y, Luo J-L, Zhou N, Li D-C, Ju H-X, et al. Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. Int J Colorectal Dis. 2015 Mar;30(3):337-45. DOI: 10.1007/s00384014-2097-2.
26. Zhou J, Shen L, Gao J. A dose escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras. Book A dose escalation study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type K-ras. EditorAmerican Society of Clinical Oncology, 2012.
27. Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, et al. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. Br J Cancer. 2016 Feb 16;114(4):372-80. DOI: 10.1038/bjc.2015.480
28. Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Rosello S, et al. Safety and Activity of the First-inClass Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov. 2015 Jun;5(6):598609. DOI: 10.1158/2159-8290.CD-14-1432
29. Lee KW, Oh D-Y, Han S-W, Kim JW, Shin J-W, Jo S-J,et al. A firstin-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Book A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors / EditorAmerican Society of Clinical Oncology, 2016.
Review
For citations:
Zabelin M.В., Kaprin A.D., Kostin A.A., Gameeva E.V., Varlamova S.E. EGFR inhibitors in the treatment of colorectal cancer. Research and Practical Medicine Journal. 2018;5(3):77-84. (In Russ.) https://doi.org/10.17709/2409-2231-2018-5-3-7
Views:
4989
Email this article 